EP3575413A1 — Phosphatidylinositol-3-kinase pathway biomarkers
Assigned to Wyeth LLC · Expires 2019-12-04 · 6y expired
What this patent protects
The invention provides a composition comprising neratinib for use in a method for treatment of breast cancer in a subject, wherein the subject is positive for the presence of one or more of: PIK3ACA gene amplification, a mutation in PIK3CA and a decrease in PTEN protein expressio…
USPTO Abstract
The invention provides a composition comprising neratinib for use in a method for treatment of breast cancer in a subject, wherein the subject is positive for the presence of one or more of: PIK3ACA gene amplification, a mutation in PIK3CA and a decrease in PTEN protein expression; and wherein the method further comprises administration of capecitabine.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.